Status:
TERMINATED
The Outcome of Chinese Women With Genitourinary Syndrome of Menopause Treated With Vaginal Dehydroepiandrosterone
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Genitourinary Syndrome of Menopause
Eligibility:
FEMALE
Brief Summary
Genitourinary syndrome of menopause (GSM) is a common condition with prevalence was up to 80%. Symptoms associated with GSM include vaginal or vulvar dryness, itchiness, dyspareunia, increased urinary...
Detailed Description
Genitourinary syndrome of menopause (GSM) is a common condition with prevalence was up to 80%. \[1\] Symptoms associated with GSM include vaginal or vulvar dryness, itchiness, dyspareunia, increased u...
Eligibility Criteria
Inclusion
- • All menopause Chinese women who have moderate to severe symptoms of Genitourinary syndrome of menopause (GSM) and treated with vaginal DHEA
Exclusion
- Genitourinary syndrome of menopause (GSM) due to other differential diagnosis such as candidiasis / lichen sclerosis/urodynamic stress incontinence/ detrusor over-activity.
- Amenorrhoea due to medication
- History of hormonal sensitive cancer, active or history of thromboembolic events, unexplained abnormal uterine bleeding
- Endometrial thickness ≥ 5mm
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 23 2023
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05434351
Start Date
August 1 2022
End Date
February 23 2023
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong, 852